BR112019016424A2 - proteínas de ligação a bcma, nkg2d e cd16 - Google Patents
proteínas de ligação a bcma, nkg2d e cd16 Download PDFInfo
- Publication number
- BR112019016424A2 BR112019016424A2 BR112019016424A BR112019016424A BR112019016424A2 BR 112019016424 A2 BR112019016424 A2 BR 112019016424A2 BR 112019016424 A BR112019016424 A BR 112019016424A BR 112019016424 A BR112019016424 A BR 112019016424A BR 112019016424 A2 BR112019016424 A2 BR 112019016424A2
- Authority
- BR
- Brazil
- Prior art keywords
- seq
- variable domain
- chain variable
- amino acid
- binding site
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762457780P | 2017-02-10 | 2017-02-10 | |
| PCT/US2018/017653 WO2018148566A1 (en) | 2017-02-10 | 2018-02-09 | Proteins binding bcma, nkg2d and cd16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019016424A2 true BR112019016424A2 (pt) | 2020-04-07 |
Family
ID=63107848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019016424A BR112019016424A2 (pt) | 2017-02-10 | 2018-02-09 | proteínas de ligação a bcma, nkg2d e cd16 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20190375838A1 (enExample) |
| EP (1) | EP3579876A4 (enExample) |
| JP (2) | JP7257323B2 (enExample) |
| KR (2) | KR20190115469A (enExample) |
| CN (1) | CN110461361A (enExample) |
| AU (1) | AU2018219348A1 (enExample) |
| BR (1) | BR112019016424A2 (enExample) |
| CA (1) | CA3054642A1 (enExample) |
| IL (1) | IL268567A (enExample) |
| MA (1) | MA47465A (enExample) |
| MX (1) | MX2019009566A (enExample) |
| MY (1) | MY205850A (enExample) |
| SG (1) | SG11201907253VA (enExample) |
| WO (1) | WO2018148566A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015248956B2 (en) * | 2014-04-14 | 2020-06-25 | Cellectis | BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy |
| EP3579848B1 (en) | 2017-02-08 | 2024-10-30 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| SG11201907253VA (en) * | 2017-02-10 | 2019-09-27 | Dragonfly Therapeutics Inc | Proteins binding bcma, nkg2d and cd16 |
| JP7685821B2 (ja) | 2017-02-20 | 2025-05-30 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｈｅｒ２、ＮＫＧ２ＤおよびＣＤ１６に結合するタンパク質 |
| SG11201913968VA (en) * | 2017-08-23 | 2020-01-30 | Dragonfly Therapeutics Inc | Proteins binding nkg2d, cd16 and a tumor-associated antigen |
| BR112020015994A2 (pt) | 2018-02-08 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer |
| MX2020008336A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Dominios variables de anticuerpos que se dirigen al receptor nkg2d. |
| JP7353576B2 (ja) | 2018-02-20 | 2023-10-02 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法 |
| EA202091977A1 (ru) * | 2018-05-28 | 2021-02-09 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения |
| EA202190468A1 (ru) | 2018-08-08 | 2021-07-06 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| SG11202101298XA (en) | 2018-08-08 | 2021-03-30 | Dragonfly Therapeutics Inc | Proteins binding nkg2d, cd16 and a tumor-associated antigen |
| US20230092679A1 (en) * | 2019-05-20 | 2023-03-23 | Novartis Ag | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| AR122018A1 (es) | 2020-05-06 | 2022-08-03 | Dragonfly Therapeutics Inc | Proteínas que se unen a nkg2d, cd16 y clec12a |
| BR112022024833A2 (pt) | 2020-06-05 | 2023-02-14 | Eisai R&D Man Co Ltd | Conjugados anticorpo anti-bcma-fármaco e métodos de uso |
| CN116063550A (zh) * | 2020-09-02 | 2023-05-05 | 南京北恒生物科技有限公司 | 靶向nk激活性受体的嵌合抗原受体 |
| CN116368154A (zh) * | 2020-10-08 | 2023-06-30 | 阿菲姆德股份有限公司 | 三特异性结合剂 |
| CN117222663A (zh) | 2021-03-03 | 2023-12-12 | 蜻蜓疗法股份有限公司 | 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法 |
| CA3210650A1 (en) | 2021-03-03 | 2022-09-09 | Winfried Wels | Bispecific antibodies enhancing cell mediated immune responses |
| TW202304992A (zh) * | 2021-03-31 | 2023-02-01 | 美商健生生物科技公司 | 用於免疫效應細胞重導向的材料及方法 |
| WO2024020577A2 (en) * | 2022-07-22 | 2024-01-25 | Fred Hutchinson Cancer Center | Antibodies against sars-cov-2 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007002905A1 (en) * | 2005-06-29 | 2007-01-04 | University Of Miami | Antibody-immune cell ligand fusion protein for cancer therapy |
| MX380352B (es) * | 2006-06-12 | 2025-03-12 | Aptevo Res & Development Llc | Proteinas de union multivalentes monocatenarias con funcion efectora. |
| AU2009204501B2 (en) * | 2008-01-07 | 2015-02-12 | Amgen Inc. | Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects |
| TW201109438A (en) | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| EP2306234A3 (de) * | 2009-10-02 | 2011-06-22 | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. | Optischer Aliasfilter, Pixelsensoranordnung und digitale Aufnahmevorrichtung |
| US9683052B2 (en) * | 2011-03-25 | 2017-06-20 | Glenmark Pharmaceuticals S.A. | Hetero-dimeric immunoglobulins |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| US20150166654A1 (en) * | 2012-05-30 | 2015-06-18 | Chugai Seiyaku Kabushiki Kaisha | Target tissue-specific antigen-binding molecule |
| KR20150023889A (ko) | 2012-06-27 | 2015-03-05 | 에프. 호프만-라 로슈 아게 | 2 개 이상의 상이한 결합 단위를 함유하는 맞춤-제작된 고도로 선별적이고 다중-특이적인 표적화 단위의 선별 및 제조 방법 및 이의 용도 |
| US10077315B2 (en) * | 2013-02-05 | 2018-09-18 | Engmab Sàrl | Bispecific antibodies against CD3 and BCMA |
| US10156574B2 (en) * | 2013-04-29 | 2018-12-18 | Adimab, Llc | Polyspecificity reagents, methods for their preparation and use |
| WO2015197582A1 (en) * | 2014-06-27 | 2015-12-30 | Innate Pharma | Monomeric multispecific antigen binding proteins |
| JP7054622B2 (ja) * | 2014-07-21 | 2022-04-14 | ノバルティス アーゲー | ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置 |
| EP3258967A4 (en) * | 2015-02-20 | 2018-10-03 | Ohio State Innovation Foundation | Bivalent antibody directed against nkg2d and tumor associated antigens |
| MX387517B (es) * | 2015-04-06 | 2025-03-18 | Subdomain Llc | Polipeptidos que contienen dominios de union de novo y usos de los mismos. |
| JP7082604B2 (ja) * | 2016-03-21 | 2022-06-08 | マレンゴ・セラピューティクス，インコーポレーテッド | 多重特異性および多機能性分子ならびにその使用 |
| EP3579848B1 (en) * | 2017-02-08 | 2024-10-30 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| WO2018148447A1 (en) * | 2017-02-08 | 2018-08-16 | Adimab, Llc | Antibody heavy chain variable domains targeting the nkg2d receptor |
| SG11201907253VA (en) * | 2017-02-10 | 2019-09-27 | Dragonfly Therapeutics Inc | Proteins binding bcma, nkg2d and cd16 |
| EP3615068A1 (en) * | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
-
2018
- 2018-02-09 SG SG11201907253VA patent/SG11201907253VA/en unknown
- 2018-02-09 MX MX2019009566A patent/MX2019009566A/es unknown
- 2018-02-09 KR KR1020197026174A patent/KR20190115469A/ko not_active Ceased
- 2018-02-09 MY MYPI2019004552A patent/MY205850A/en unknown
- 2018-02-09 US US16/484,936 patent/US20190375838A1/en active Pending
- 2018-02-09 JP JP2019543761A patent/JP7257323B2/ja active Active
- 2018-02-09 WO PCT/US2018/017653 patent/WO2018148566A1/en not_active Ceased
- 2018-02-09 AU AU2018219348A patent/AU2018219348A1/en not_active Abandoned
- 2018-02-09 KR KR1020247004861A patent/KR20240078657A/ko not_active Ceased
- 2018-02-09 BR BR112019016424A patent/BR112019016424A2/pt not_active Application Discontinuation
- 2018-02-09 MA MA047465A patent/MA47465A/fr unknown
- 2018-02-09 CN CN201880021558.4A patent/CN110461361A/zh active Pending
- 2018-02-09 CA CA3054642A patent/CA3054642A1/en active Pending
- 2018-02-09 EP EP18750616.7A patent/EP3579876A4/en active Pending
-
2019
- 2019-08-07 IL IL268567A patent/IL268567A/en unknown
-
2022
- 2022-12-08 JP JP2022196214A patent/JP2023029988A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2019009566A (es) | 2020-01-20 |
| JP7257323B2 (ja) | 2023-04-13 |
| RU2019127910A (ru) | 2021-03-10 |
| EP3579876A4 (en) | 2020-11-18 |
| JP2020507328A (ja) | 2020-03-12 |
| IL268567A (en) | 2019-09-26 |
| WO2018148566A1 (en) | 2018-08-16 |
| CN110461361A (zh) | 2019-11-15 |
| KR20240078657A (ko) | 2024-06-04 |
| MA47465A (fr) | 2019-12-18 |
| SG11201907253VA (en) | 2019-09-27 |
| EP3579876A1 (en) | 2019-12-18 |
| KR20190115469A (ko) | 2019-10-11 |
| AU2018219348A1 (en) | 2019-08-29 |
| CA3054642A1 (en) | 2018-08-16 |
| MY205850A (en) | 2024-11-15 |
| JP2023029988A (ja) | 2023-03-07 |
| US20190375838A1 (en) | 2019-12-12 |
| RU2019127910A3 (enExample) | 2021-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018220734B2 (en) | Proteins binding CD33, NKG2D and CD16 | |
| US20200277384A1 (en) | Proteins binding nkg2d, cd16, and c-type lectin-like molecule-1 (cll-1) | |
| BR112019016424A2 (pt) | proteínas de ligação a bcma, nkg2d e cd16 | |
| US20240018266A1 (en) | Proteins binding cd123, nkg2d and cd16 | |
| US20210130496A1 (en) | Multispecific binding proteins targeting cea | |
| US20200157174A1 (en) | Proteins binding nkg2d, cd16 and ror1 or ror2 | |
| US20200165344A1 (en) | Proteins binding nkg2d, cd16 and flt3 | |
| BR112019017197A2 (pt) | proteínas que se ligam a her2, nkg2d e cd16 | |
| WO2019051308A1 (en) | NKG2D, CD16 BINDING PROTEINS AND ANTIGEN ASSOCIATED WITH A TUMOR | |
| EP3630181A1 (en) | A protein binding nkg2d, cd16 and a tumor-associated antigen | |
| US20200024353A1 (en) | Proteins binding psma, nkg2d and cd16 | |
| US20200231700A1 (en) | Proteins binding gd2, nkg2d and cd16 | |
| BR112019016315A2 (pt) | Proteínas de ligação multiespecíficas para ativação de células natural killer e usos terapêuticos destas para tratamento de câncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B25G | Requested change of headquarter approved |
Owner name: DRAGONFLY THERAPEUTICS, INC. (US) |
|
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |